人福医药(600079.SH)子公司重组质粒-肝细胞生长因子注射液上市许可申请获受理

智通财经12-04

智通财经APP讯，人福医药(600079.SH)发布公告，公司控股子公司武汉光谷人福生物医药有限公司(简称“光谷人福”，公司持有其81.30%的股权)近日收到国家药品监督管理局核准签发的重组质粒-肝细胞生长因子注射液药品注册上市许可申请《受理通知书》。重组质粒-肝细胞生长因子注射液(以下简称“pUDK-HGF”)适用于治疗严重下肢缺血性疾病导致的肢体静息痛。截至目前，光谷人福该项目累计研发投入约为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2488515681?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-04 16:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488515681","market":"sh","top_or_hot":-1,"title":"人福医药(600079.SH)子公司重组质粒-肝细胞生长因子注射液上市许可申请获受理","media":"智通财经","content":"<div>\n<p>智通财经APP讯，人福医药(600079.SH)发布公告，公司控股子公司武汉光谷人福生物医药有限公司(简称“光谷人福”，公司持有其81.30%的股权)近日收到国家药品监督管理局核准签发的重组质粒-肝细胞生长因子注射液药品注册上市许可申请《受理通知书》。重组质粒-肝细胞生长因子注射液(以下简称“pUDK-HGF”)适用于治疗严重下肢缺血性疾病导致的肢体静息痛。截至目前，光谷人福该项目累计研发投入约为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1220251.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>人福医药(600079.SH)子公司重组质粒-肝细胞生长因子注射液上市许可申请获受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n人福医药(600079.SH)子公司重组质粒-肝细胞生长因子注射液上市许可申请获受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-04 16:50 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1220251.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，人福医药(600079.SH)发布公告，公司控股子公司武汉光谷人福生物医药有限公司(简称“光谷人福”，公司持有其81.30%的股权)近日收到国家药品监督管理局核准签发的重组质粒-肝细胞生长因子注射液药品注册上市许可申请《受理通知书》。重组质粒-肝细胞生长因子注射液(以下简称“pUDK-HGF”)适用于治疗严重下肢缺血性疾病导致的肢体静息痛。截至目前，光谷人福该项目累计研发投入约为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1220251.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1220251.html","article_id":"2488515681","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488515681","pubTimestamp":1733302228,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，人福医药 发布公告，公司控股子公司武汉光谷人福生物医药有限公司近日收到国家药品监督管理局核准签发的重组质粒-肝细胞生长因子注射液药品注册上市许可申请《受理通知书》。重组质粒-肝细胞生长因子注射液药品注册上市许可申请被国家药品监督管理局受理，标志着该品种境内生产药品注册工作进入了审评阶段，公司将积极推进后续相关工作，如顺利通过审评审批，将丰富公司的产品线，有利于提升公司的市场竞争力。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600079":"人福医药","BK0239":"医药制造","BK0185":"二线龙头","BK0028":"国家队","BK0096":"民营医院","BK0070":"员工持股","BK0188":"融资融券","BK0012":"证金概念"},"translate_title":"Renfu Pharmaceutical (600079. SH) subsidiary recombinant plasmid-hepatocyte growth factor injection marketing authorization application accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600079":1},"content_text":"智通财经APP讯，人福医药(600079.SH)发布公告，公司控股子公司武汉光谷人福生物医药有限公司(简称“光谷人福”，公司持有其81.30%的股权)近日收到国家药品监督管理局核准签发的重组质粒-肝细胞生长因子注射液药品注册上市许可申请《受理通知书》。重组质粒-肝细胞生长因子注射液(以下简称“pUDK-HGF”)适用于治疗严重下肢缺血性疾病导致的肢体静息痛。截至目前，光谷人福该项目累计研发投入约为人民币1.6亿元。pUDK-HGF为治疗用生物制品1类新药，目前国内尚无同类型产品上市。根据北京诺思兰德生物技术股份有限公司官方网站显示，其研发的治疗用生物制品1类新药塞多明基注射液——“重组人肝细胞生长因子裸质粒注射液(代号NL003)”上市许可申请已获受理(适应症为严重下肢缺血导致的肢体溃疡);根据国家药品监督管理局药品审评中心网站药物临床试验登记与信息公示平台显示，其静息痛适应症III期临床试验已完成。重组质粒-肝细胞生长因子注射液药品注册上市许可申请被国家药品监督管理局受理，标志着该品种境内生产药品注册工作进入了审评阶段，公司将积极推进后续相关工作，如顺利通过审评审批，将丰富公司的产品线，有利于提升公司的市场竞争力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488515681"}